Valerius T - Search Results

1

HLA class II antibodies in the treatment of hematologic malignancies.

Dechant M, Bruenke J, Valerius T. Dechant M, et al. Among authors: valerius t. Semin Oncol. 2003 Aug;30(4):465-75. doi: 10.1016/s0093-7754(03)00252-5. Semin Oncol. 2003. PMID: 12939715 Review.

2

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.

Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M. Elsässer D, et al. Among authors: valerius t. Blood. 1996 May 1;87(9):3803-12. Blood. 1996. PMID: 8611706 Free article.

3

HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies.

Valerius T, Elsässer D, Repp R, Van de Winkel JG, Gramatzki M, Glennie M. Valerius T, et al. Leuk Lymphoma. 1997 Jul;26(3-4):261-9. doi: 10.3109/10428199709051775. Leuk Lymphoma. 1997. PMID: 9322888 Review.

4

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

5

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.

Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, van Royen EA, Capel PJ, van de Winkel JG. Heijnen IA, et al. Among authors: valerius t. J Immunol. 1997 Dec 1;159(11):5629-39. J Immunol. 1997. PMID: 9548506

6

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: valerius t. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

7

Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.

Elsässer D, Stadick H, Stark S, Van de Winkel JG, Gramatzki M, Schrott KM, Valerius T, Schafhauser W. Elsässer D, et al. Among authors: valerius t. Anticancer Res. 1999 Mar-Apr;19(2C):1525-8. Anticancer Res. 1999. PMID: 10365137

8

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: valerius t. J Immunol. 2000 Nov 15;165(10):5954-61. doi: 10.4049/jimmunol.165.10.5954. J Immunol. 2000. PMID: 11067958

9

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.

Stockmeyer B, Elsässer D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: valerius t. J Immunol Methods. 2001 Feb 1;248(1-2):103-11. doi: 10.1016/s0022-1759(00)00346-x. J Immunol Methods. 2001. PMID: 11223072

10

IgA antibodies for cancer therapy.

Dechant M, Valerius T. Dechant M, et al. Among authors: valerius t. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):69-77. doi: 10.1016/s1040-8428(01)00105-6. Crit Rev Oncol Hematol. 2001. PMID: 11418303 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters